1 / 3

Gilead Licenses Remdesivir to Generic Companies For Sale in 127 Countries

Remdesivir is considered a key drug in the fight against COVID-19 as a randomised clinical trial conducted with the drug on 1,063 patients over 60 centres across US, Europe and Asia demonstrated a faster time to clinical recovery in hospitalised patients as compared to placebo.

sunnyfang1419
Download Presentation

Gilead Licenses Remdesivir to Generic Companies For Sale in 127 Countries

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Huateng Pharma https://en.huatengsci.com Gilead Licenses Remdesivir to Generic Companies For Sale in 127 Countries Gilead Sciences, Inc. said it has signed non-exclusive voluntary licensing agreements with nine generic pharmaceutical manufacturers based in India, Pakistan and Eygpt to manufacture and distribute COVID-19 therapy remdesivir to 127 countries. Remdesivir is considered a key drug in the fight against COVID-19 as a randomised clinical trial conducted with the drug on 1,063 patients over 60 centres across US, Europe and Asia demonstrated a faster time to clinical recovery in hospitalised patients as compared to placebo. ​ The agreements allow the companies – Cipla Ltd.; Dr. Reddy's Laboratories Ltd.; Eva Pharma; Ferozsons Laboratories; Hetero Labs Ltd.; Jubilant Lifesciences; Mylan; Syngene, a Biocon company; and Zydus Cadila Healthcare Ltd. – to manufacture remdesivir for distribution in 127 countries. Company Country Approval Price ₹4,000 per 100 mg vial Cipla India Approved

  2. Huateng Pharma https://en.huatengsci.com ₹5,400 per 100 mg vial ₹4,800 per 100 mg vial Hetero India Approved Mylan India Approved Dr. Reddy's Laboratories Ltd. Jubilant Lifesciences Pending for approval Pending for approval Pending for approval Pending for approval Pending for approval Pending for approval India N/A India N/A Syngene India N/A Zydus Cadila Healthcare Ltd. India N/A Eva Pharma Egypt N/A Ferozsons Laboratories Table 1: Companies licensed for remdesivir manufacturing Pakistan N/A The countries consist of nearly all low-income and lower-middle income countries, as well as several upper-middle- and high-income countries that face significant obstacles to healthcare access. Afghanistan Botswana British Virgin Islands Cuba Grenada Lesotho Myanmar Seychelles Timor-Leste Algeria Curacao Guatemala Liberia Namibia Sierra Leone Togo Sint Maarten (Dutch part) Solomon Islands Angola Burkina Faso Djibouti Guinea Libya Nauru Tonga Trinidad & Tobago Anguilla Burundi Dominica Guinea Bis Madagascar Nepal Antigua & Barbuda Armenia Dominican Republic Egypt Cambodia Guyana Malawi Nicaragua Somalia Tunisia Cameroon Haiti Maldives Niger South Africa Turkmenistan Turks & Caicos Aruba Cape Verde El Salvador Honduras Mali Nigeria South Sudan Cayman Island Equatorial Guinea Marshall Islands Azerbaijan India Pakistan Sri Lanka Tuvalu St. Kitts and Nevis Bahamas, The Central Af R. Eritrea Indonesia Mauritania Palau Uganda Eswatini (Swaziland) Bangladesh Chad Jamaica Mauritius Panama St. Lucia Ukraine St. Vincent and the Grenadines Sudan Micronesia, Fed. Sts. Papua New Guinea Barbados Comoros Ethiopia Kazakhstan Uzbekistan Belarus Congo DR Fiji Kenya Moldova Philippines Vanuatu

  3. Huateng Pharma https://en.huatengsci.com Belize Congo Rep. Gabon Kiribati Korea, Dem. People's Rep. (North Korea) Mongolia Rwanda Suriname Vietnam Benin Cook Islands Gambia, The Montserrat Samoa Tajikistan Zambia Sao Tome and Principe Senegal Bermuda Costa Rica Georgia Kyrgyzstan Morocco Tanzania Zimbabwe Bhutan Cote d’Ivoire Ghana Lao DR (Laos) Mozambique permitted distribution by the agreements ​ Thailand Table 2: Countries​ The regulatory approval status of remdesivir varies by country, and the distribution of remdesivir within each country is subject to local laws and regulations. Under the licensing agreements, the companies have a right to receive a technology transfer of the Gilead manufacturing process for remdesivir to enable them to scale up production more quickly. The licensees also set their own prices for the generic product they produce. The licenses are royalty-free until the World Health Organization declares the end of the Public Health Emergency of International Concern regarding Covid-19, or until a pharmaceutical product other than remdesivir or a vaccine is approved to treat or prevent Covid-19, whichever is earlier. Related Articles: COVID-19 Vaccine Data Raises Hope for Three of Candidates An Antiviral Drug Favipiravir Was Approved For Treating Against COVID-19 UK Approved The Use Of Remdesivir To Treat Some COVID-19 Patients Three Remdesivir Trials: One Shows Promise for Treating Coronavirus

More Related